O slideshow foi denunciado.
Utilizamos seu perfil e dados de atividades no LinkedIn para personalizar e exibir anúncios mais relevantes. Altere suas preferências de anúncios quando desejar.

The Number and Price of Orphan Drugs

182 visualizações

Publicada em

Mikko Seppänen, MD, PhD, Associate Professor
Specialist in Internal Medicine and Infectious
Diseases
Clinical Immunologist
Head, Rare Disease Center of HUS

Publicada em: Saúde e medicina
  • Seja o primeiro a comentar

  • Seja a primeira pessoa a gostar disto

The Number and Price of Orphan Drugs

  1. 1. 4/15/2016 1 THE NUMBER AND PRICE OF ORPHAN DRUGS Mikko Seppänen, MD, PhD, Associate Professor Specialist in Internal Medicine and Infectious Diseases Clinical Immunologist Head, Rare Disease Center of HUS ORPHAN DRUGS • Before 1983: 38 orphan drugs for rare diseases • US Orphan Drug Act 1983; Japanese 1993; EMA 2000 • Criteria – for the treatment, prevention or diagnosis of a life-threatening or chronically debilitating disease – prevalence of condition in EU ≤5:10,000 or unlikely that marketing would generate sufficient returns to justify the investment needed for its development • US: <6.37:10,000, Japan <4:10,000 – no satisfactory method of diagnosis, prevention or treatment of the condition concerned can be authorized,or, if exists, the medicine must be of significant benefit to those affected by the condition. • Applications evaluated by EMA Committee for Orphan Medicinal Products (COMP) – 10 years of marketing exclusivity from approval (US: “7 years, 50% tax credit, R&D funding) – by far less strict premarketing research criteria OD - FINANCIAL FIGURES • 12% annual growth (other drugs 6%) • In 2020 predicted that ODs will cover – 20% of total drug market – 178 billion USD = 178,000,000,000 USD • Advantages for pharmaceutical industry in OD development – lack of alternatives for patients – lower R&D costs – easily defined patient populations – prices that the drugs are able to command • So far orphan drug developers have managed to defend the cost of these life-changing drugs due to – relatively small patient populations they serve – continued paucity of options for sufferers www.evaluategroup.com/orphandrug2015 OD DESIGNATIONS • Orphan drug designations (n) increased in 2014 – Europe: to n=201 (62% ↑) – US: to n=291 (12% ↑) – currently >15-20 new drugs into market yearly • will it become harder to justify prices? http://ec.europa.eu/health/documents/community-register/html/alforphreg.htm OD DESIGNATIONS • Cumulative numbers of designations rarely known by policy makers or by treating physicians • Exclusivity = freedom from competition – if medically superior – does not increase competitive bidding & pricing OD PRICING • Strensiq® /primary hypophosphatasia: >2 million €/y /adult 80 kg patient http://apps.who.int/medicinedocs/documents/s21793en/s21793en.pdf
  2. 2. 4/15/2016 2 OD PRICING VS DEVELOPMENT COST Development cost OD PRICING AND PROBLEMS • High pricing will drain an increasing amount of invaluable resources in health care? – how will we afford all these drugs? – prioritization, based on what? • expected/proven gain in survival/ QALY? • ”the acceptable cost of human life year???” England: acceptable cost per QALY: 360,000-1,360,000€ Ivacaftor/CF:335,00 -1,274,000 GBP/year • is survival >> reduced complications w/o shown survival benefit (yet?)? – prioritization should not be done by the treating physician • Ethical questions – politicians and policy makers (understandably) reluctant to consider – either way … if politically can or cannot be afforded • Will EMA and FDA be able to…???? markets are global… – create more transparency – define acceptable profit margins THANKS • 19,4% (296/1525) against diseases with prevalence <0.2:10 000
  3. 3. 4/15/2016 3

×